Vol. 8 (2021): In progress

Published: 2021-08-05

Original Research Article

Metastatic renal cancer: real-world evidence from a large Italian claims database

Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Silvia Calabria, Anna Capponcelli, Antonella Pedrini, Maurizio Marangolo, Immacolata Esposito, Carmine Pinto, Nello Martini

1-7
- PDF
- ePub
- html
Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo

8-13
- PDF
- ePub
- html
A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

Sergio Iannazzo

14-21
- PDF
- ePub
- html
The future of Funds for Innovative Medicines: results from a Delphi Study

Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto

22-28
- PDF
- ePub
- html
Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

Marco Chiumente, Alberto Russi, Federica Todino, Daniele Mengato, Marina Coppola, Melania Rivano, Angelo Claudio Palozzo, Claudio Jommi

29-34
- PDF
- ePub
- html
Costs of the management of hemophilia A with inhibitors in Spain

Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez

35-42
- PDF
- ePub
- html
Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

Giovanni Di Minno, Roberto Ravasio

43-52
- PDF
- ePub
- html
- PDF (Italian)
- ePub (Italian)
- html (Italian)
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi

53-57
- PDF
- ePub
- html
The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Stefano Fagiuoli, Matteo Ruggeri, Filipa Aragao, Rob Blissett

58-66
- PDF
- ePub
- html
Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

69-79
- PDF
- ePub
- html
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

Mario Boccadoro, Patrizia Berto, Sara Bringhen, Elena Zamagni, Patrizia Tosi, Nicola Cascavilla, Nicola Giuliani, Donato Mannina, Renato Zambello, Francesca Patriarca, Vittorio Montefusco, Mariella Grasso, Francesco Di Raimondo, Massimo Offidani, Maria Teresa Petrucci, Pellegrino Musto

80-86
- PDF
- ePub
- html
Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

Michele Basile, Filippo Rumi, Americo Cicchetti

87-95
- PDF
- ePub
- html
Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

Michele Basile, Lorenzo Somaini, Americo Cicchetti

96-104
- PDF
- ePub
- html
Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

Filippo Rumi, Michele Basile, Americo Cicchetti

105-113
- PDF
- ePub
- html
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio

120-130
- PDF
- ePub
- html

Correspondence

Point of View

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler

114-119
- PDF
- ePub
- html
New drug pricing criteria in Italy: considerations and proposals to support value and innovation

Francesca Patarnello, Federico Villa

131-133
- PDF
- ePub
- html
Real-world data: how they can help to improve quality of care

Giovanni Corrao, Giovanni Alquati, Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Giorgio W. Canonica, Pierfranco Conte, Elisa Crovato, Francesco Damele, Carlo La Vecchia, Aldo P. Maggioni, Alberto Mantovani, Michele Marangi, Walter Marrocco, Andrea Messori, Alessandro Padovani, Alessandro Rambaldi, Walter Ricciardi, Francesco Ripa di Meana, Federico Spandonaro, Valeria Tozzi, Giuseppe Mancia

134-139
- PDF
- ePub
- html

Vol. 8 (2021): In progress

Original Research Article

Metastatic renal cancer: real-world evidence from a large Italian claims database

Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

The future of Funds for Innovative Medicines: results from a Delphi Study

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

Costs of the management of hemophilia A with inhibitors in Spain

Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Correspondence

Correspondence to article "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain"

Author’s reply to comments on “Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain”

Point of View

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

New drug pricing criteria in Italy: considerations and proposals to support value and innovation

Real-world data: how they can help to improve quality of care

banners150

Usage Statistics Information